000138594 001__ 138594
000138594 005__ 20240321220452.0
000138594 0247_ $$2doi$$a10.1161/STROKEAHA.115.011321
000138594 0247_ $$2pmid$$apmid:26658450
000138594 0247_ $$2ISSN$$a0039-2499
000138594 0247_ $$2ISSN$$a1524-4628
000138594 0247_ $$2altmetric$$aaltmetric:4880430
000138594 037__ $$aDZNE-2020-04916
000138594 041__ $$aEnglish
000138594 082__ $$a610
000138594 1001_ $$0P:(DE-HGF)0$$aHong, Ja Bin$$b0
000138594 245__ $$aAnkle-Brachial Index and Recurrent Stroke Risk: Meta-Analysis.
000138594 260__ $$aPhiladelphia, Pa.$$bLippincott Williams & Wilkins$$c2016
000138594 264_1 $$2Crossref$$3print$$bOvid Technologies (Wolters Kluwer Health)$$c2016-02-01
000138594 3367_ $$2DRIVER$$aarticle
000138594 3367_ $$2DataCite$$aOutput Types/Journal article
000138594 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1586181083_31018
000138594 3367_ $$2BibTeX$$aARTICLE
000138594 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000138594 3367_ $$00$$2EndNote$$aJournal Article
000138594 520__ $$aThe ankle-brachial index (ABI) is a fast, cheap, noninvasive indicator of atherosclerotic burden that may also be a predictor of stroke recurrence. In this systematic review and meta-analysis, we sought to explore ABI's merit as a marker for stroke recurrence and vascular risk by synthesizing the data currently available in stroke literature.We searched Embase, MEDLINE, and Pubmed databases for prospective cohort studies that included consecutive patients with stroke and transient ischemic attack, measured ABI at baseline, and performed a follow-up assessment at least 12 months after initial stroke or transient ischemic attack. The following end points were chosen for our analysis: recurrent stroke and combined vascular end point (recurrent vascular event or vascular death). Crude risk ratios and adjusted Cox proportional hazard ratios were combined separately using the random-effects model. Study-level characteristics (eg, percent of cohort with a history of hypertension, average cohort age, level of adjustment, and mean follow-up duration) were included as covariates in a metaregression analysis.We identified 11 studies (5374 patients) that were not significantly heterogeneous. Pooling adjusted hazard ratios showed that low ABI was associated with both an increased hazard of recurrent stroke (hazard ratio, 1.70; 95% confidence interval, 1.10-2.64) and an increased risk of vascular events or vascular death (hazard ratio, 2.22; 95% confidence interval, 1.67-2.97).Our results confirm the positive association between ABI and stroke recurrence. Further studies are needed to see whether inclusion of ABI will help improve the accuracy of prediction models and management of stroke patients.
000138594 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000138594 588__ $$aDataset connected to CrossRef, PubMed,
000138594 650_2 $$2MeSH$$aAge Factors
000138594 650_2 $$2MeSH$$aAnkle Brachial Index: statistics & numerical data
000138594 650_2 $$2MeSH$$aAtherosclerosis: epidemiology
000138594 650_2 $$2MeSH$$aAtherosclerosis: physiopathology
000138594 650_2 $$2MeSH$$aHumans
000138594 650_2 $$2MeSH$$aHypertension: epidemiology
000138594 650_2 $$2MeSH$$aIschemic Attack, Transient: epidemiology
000138594 650_2 $$2MeSH$$aMultivariate Analysis
000138594 650_2 $$2MeSH$$aOdds Ratio
000138594 650_2 $$2MeSH$$aProportional Hazards Models
000138594 650_2 $$2MeSH$$aRecurrence
000138594 650_2 $$2MeSH$$aRisk Assessment
000138594 650_2 $$2MeSH$$aSeverity of Illness Index
000138594 650_2 $$2MeSH$$aStroke: epidemiology
000138594 7001_ $$0P:(DE-HGF)0$$aLeonards, Christopher O$$b1
000138594 7001_ $$0P:(DE-2719)2811033$$aEndres, Matthias$$b2$$udzne
000138594 7001_ $$0P:(DE-HGF)0$$aSiegerink, Bob$$b3
000138594 7001_ $$0P:(DE-HGF)0$$aLiman, Thomas G$$b4$$eCorresponding author
000138594 77318 $$2Crossref$$3journal-article$$a10.1161/strokeaha.115.011321$$b : Ovid Technologies (Wolters Kluwer Health), 2016-02-01$$n2$$p317-322$$tStroke$$v47$$x0039-2499$$y2016
000138594 773__ $$0PERI:(DE-600)1467823-8$$a10.1161/STROKEAHA.115.011321$$gVol. 47, no. 2, p. 317 - 322$$n2$$p317-322$$q47:2<317 - 322$$tStroke$$v47$$x0039-2499$$y2016
000138594 909CO $$ooai:pub.dzne.de:138594$$pVDB
000138594 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811033$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000138594 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$aDE-HGF$$bForschungsbereich Gesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000138594 9141_ $$y2016
000138594 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000138594 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000138594 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000138594 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000138594 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000138594 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTROKE : 2017
000138594 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000138594 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000138594 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000138594 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000138594 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000138594 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000138594 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000138594 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bSTROKE : 2017
000138594 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lCoordinator of Clinical Research$$x0
000138594 980__ $$ajournal
000138594 980__ $$aVDB
000138594 980__ $$aI:(DE-2719)1811005
000138594 980__ $$aUNRESTRICTED
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1161/strokeaha.110.602615$$o10.1161/strokeaha.110.602615
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1001/archinte.167.22.2417$$o10.1001/archinte.167.22.2417
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1177/1358863X10378376$$o10.1177/1358863X10378376
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jacc.2010.04.060$$o10.1016/j.jacc.2010.04.060
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1161/01.atv.0000168911.78624.b7$$o10.1161/01.atv.0000168911.78624.b7
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1001/jama.300.2.197$$o10.1001/jama.300.2.197
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.atherosclerosis.2006.03.011$$o10.1016/j.atherosclerosis.2006.03.011
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1177/2047487313516564$$o10.1177/2047487313516564
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.atherosclerosis.2015.05.017$$o10.1016/j.atherosclerosis.2015.05.017
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1161/strokeaha.109.559278$$o10.1161/strokeaha.109.559278
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1468-1331.2009.02874.x$$o10.1111/j.1468-1331.2009.02874.x
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.atherosclerosis.2013.12.034$$o10.1016/j.atherosclerosis.2013.12.034
000138594 999C5 $$2Crossref$$oMilionis H 2013$$y2013
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1024/0301-1526/a000328$$o10.1024/0301-1526/a000328
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1001/jama.283.15.2008$$o10.1001/jama.283.15.2008
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.7326/0003-4819-151-4-200908180-00135$$o10.7326/0003-4819-151-4-200908180-00135
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1136/bmj.327.7414.557$$o10.1136/bmj.327.7414.557
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/sim.2380$$o10.1002/sim.2380
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.atherosclerosis.2011.11.009$$o10.1016/j.atherosclerosis.2011.11.009
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1186/1471-2377-12-102$$o10.1186/1471-2377-12-102
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1024/0301-1526/a000266$$o10.1024/0301-1526/a000266
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1159/000306640$$o10.1159/000306640
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.atherosclerosis.2011.10.037$$o10.1016/j.atherosclerosis.2011.10.037
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1161/atvb.19.3.538$$o10.1161/atvb.19.3.538
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ahj.2004.07.019$$o10.1016/j.ahj.2004.07.019
000138594 999C5 $$2Crossref$$oLi CY 2012$$y2012
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1538-7836.2006.02225.x$$o10.1111/j.1538-7836.2006.02225.x
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/ene.12253$$o10.1111/ene.12253
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1161/strokeaha.109.559740$$o10.1161/strokeaha.109.559740
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1159/000323233$$o10.1159/000323233
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.atherosclerosis.2012.04.009$$o10.1016/j.atherosclerosis.2012.04.009
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1186/s12883-015-0278-4$$o10.1186/s12883-015-0278-4
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1136/jnnp.2008.146092$$o10.1136/jnnp.2008.146092
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1468-1331.2011.03510.x$$o10.1111/j.1468-1331.2011.03510.x
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.atherosclerosis.2013.05.014$$o10.1016/j.atherosclerosis.2013.05.014
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1186/1471-2288-9-56$$o10.1186/1471-2288-9-56
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1161/strokeaha.110.582627$$o10.1161/strokeaha.110.582627
000138594 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1161/str.0000000000000024$$o10.1161/str.0000000000000024